Related Experiment Video
Updated: Jun 1, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
New Paradigms in Theranostics of Prostate Cancer: The Rise of α-Emitters and Next-generation Targets
Désirée Deandreis1, Eric Deutsch2
1Nuclear Medicine Division, Medical Imaging Department, Gustave Roussy; Biomaps UMR 1281, INSERM, CNRS, CEA, Université Paris-Saclay, Villejuif, France.
Abstract:
Radioligand therapy (RLT) with [177Lu]Lutetium-PSMA (prostate specific membrane antigen) has become a pillar of prostate cancer treatment; however, resistance and PSMA-negative disease remain as unmet needs. The α-emitting radionuclides represent a paradigm shift, with physical properties suited to overcome β-emitter resistance. [225Ac]Actinium-PSMA (prostate specific membrane antigen) has shown promising retrospective results, and ongoing trials are refining its sequencing and safety. Astatine-211 and lead-212 may further improve dosimetry and supply scalability. Beyond PSMA, emerging targets could extend theranostics to PSMA-negative and neuroendocrine diseases. Biomarker-stratified trials will be essential to personalize RLT in prostate cancer. PATIENT SUMMARY: This review highlights future directions in radioligand therapy for advanced prostate cancer, including α-therapy, and the identification of novel targets that may open new therapeutic options for prostate-specific membrane antigen-negative disease.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

